Regencell Bioscience Holdings Limited (RGC)
USD 36.67
(29.85%)
USD 36.67
(29.85%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 | - USD | 0.0% |
| 2023 | 25.4 Thousand USD | -92.95% |
| 2022 | 360.26 Thousand USD | 0.0% |
| 2021 | - USD | 0.0% |
| 2020 | - USD | 0.0% |
| 2019 | - USD | -100.0% |
| 2018 | 2.33 Billion USD | 6.48% |
| 2017 | 2.19 Billion USD | -1.4% |
| 2016 | 2.22 Billion USD | -0.47% |
| 2015 | 2.23 Billion USD | 0.0% |
| 2013 | 2.18 Billion USD | 14.4% |
| 2012 | 1.91 Billion USD | 0.77% |
| 2011 | 1.89 Billion USD | 0.27% |
| 2010 | 1.89 Billion USD | 2357.92% |
| 2009 | 77 Million USD | 0.0% |
| 2007 | 54 Million USD | -11.48% |
| 2006 | 61 Million USD | 10.91% |
| 2005 | 55 Million USD | -22.54% |
| 2004 | 71 Million USD | 0.0% |
| 2002 | 109 Million USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | - USD | 0.0% |
| 2024 Q2 | - USD | 0.0% |
| 2024 Q4 | - USD | 0.0% |
| 2023 Q1 | - USD | -100.0% |
| 2023 Q2 | - USD | 0.0% |
| 2023 Q4 | 25.4 Thousand USD | 0.0% |
| 2023 FY | 25.4 Thousand USD | -92.95% |
| 2023 Q3 | 25.4 Thousand USD | 0.0% |
| 2022 Q4 | 360.26 Thousand USD | 0.0% |
| 2022 FY | 360.26 Thousand USD | 0.0% |
| 2022 Q3 | 360.26 Thousand USD | 0.0% |
| 2022 Q1 | - USD | 0.0% |
| 2022 Q2 | - USD | 0.0% |
| 2021 Q1 | - USD | 0.0% |
| 2021 FY | - USD | 0.0% |
| 2021 Q4 | - USD | 0.0% |
| 2021 Q2 | - USD | 0.0% |
| 2021 Q3 | - USD | 0.0% |
| 2020 Q3 | - USD | 0.0% |
| 2020 Q1 | - USD | 0.0% |
| 2020 FY | - USD | 0.0% |
| 2020 Q4 | - USD | 0.0% |
| 2019 FY | - USD | -100.0% |
| 2018 Q1 | 2.34 Billion USD | -0.06% |
| 2018 Q2 | 2.33 Billion USD | -0.12% |
| 2018 FY | 2.33 Billion USD | 6.48% |
| 2017 Q4 | 2.34 Billion USD | 6.73% |
| 2017 Q1 | 2.19 Billion USD | -0.05% |
| 2017 Q2 | 2.19 Billion USD | 0.02% |
| 2017 Q3 | 2.19 Billion USD | -0.05% |
| 2017 FY | 2.19 Billion USD | -1.4% |
| 2016 Q1 | 2.23 Billion USD | -0.16% |
| 2016 FY | 2.22 Billion USD | -0.47% |
| 2016 Q4 | 2.19 Billion USD | 0.07% |
| 2016 Q3 | 2.19 Billion USD | -1.43% |
| 2016 Q2 | 2.22 Billion USD | -0.17% |
| 2015 FY | 2.23 Billion USD | 0.0% |
| 2015 Q1 | 2.24 Billion USD | -0.16% |
| 2015 Q4 | 2.23 Billion USD | 0.03% |
| 2015 Q3 | 2.23 Billion USD | -0.17% |
| 2015 Q2 | 2.23 Billion USD | -0.17% |
| 2014 Q2 | 2.18 Billion USD | 0.09% |
| 2014 Q4 | 2.24 Billion USD | -5.72% |
| 2014 Q3 | 2.38 Billion USD | 8.92% |
| 2014 Q1 | 2.18 Billion USD | -0.16% |
| 2013 FY | 2.18 Billion USD | 14.4% |
| 2013 Q4 | 2.18 Billion USD | 1.42% |
| 2013 Q2 | 1.91 Billion USD | -0.14% |
| 2013 Q3 | 2.15 Billion USD | 12.88% |
| 2013 Q1 | 1.91 Billion USD | -0.19% |
| 2012 Q2 | 1.92 Billion USD | -0.14% |
| 2012 FY | 1.91 Billion USD | 0.77% |
| 2012 Q4 | 1.91 Billion USD | -0.14% |
| 2012 Q3 | 1.92 Billion USD | -0.19% |
| 2012 Q1 | 1.92 Billion USD | -0.18% |
| 2011 Q2 | 1.89 Billion USD | -2.76% |
| 2011 Q1 | 1.95 Billion USD | 16.39% |
| 2011 Q3 | 1.93 Billion USD | 1.91% |
| 2011 FY | 1.89 Billion USD | 0.27% |
| 2011 Q4 | 1.93 Billion USD | -0.14% |
| 2010 Q1 | 58 Million USD | -25.64% |
| 2010 Q3 | 58 Million USD | -96.94% |
| 2010 Q4 | 1.67 Billion USD | 2791.03% |
| 2010 Q2 | 1.89 Billion USD | 3163.1% |
| 2010 FY | 1.89 Billion USD | 2357.92% |
| 2009 FY | 77 Million USD | 0.0% |
| 2009 Q1 | 55 Million USD | -17.91% |
| 2009 Q2 | 77 Million USD | 40.0% |
| 2009 Q3 | 58 Million USD | -24.68% |
| 2009 Q4 | 78 Million USD | 34.48% |
| 2008 Q4 | 67 Million USD | 55.81% |
| 2008 Q2 | 54 Million USD | 12.5% |
| 2008 Q3 | 43 Million USD | -20.37% |
| 2008 Q1 | 48 Million USD | -15.79% |
| 2007 Q4 | 57 Million USD | 21.28% |
| 2007 FY | 54 Million USD | -11.48% |
| 2007 Q3 | 47 Million USD | -22.95% |
| 2007 Q2 | 61 Million USD | -23.75% |
| 2007 Q1 | 80 Million USD | -1.23% |
| 2006 Q4 | 81 Million USD | 14.08% |
| 2006 Q3 | 71 Million USD | -19.32% |
| 2006 Q2 | 88 Million USD | 39.68% |
| 2006 Q1 | 63 Million USD | -96.31% |
| 2006 FY | 61 Million USD | 10.91% |
| 2005 Q2 | 55 Million USD | -96.81% |
| 2005 FY | 55 Million USD | -22.54% |
| 2005 Q1 | 1.72 Billion USD | 3565.74% |
| 2005 Q3 | 1.62 Billion USD | 2850.73% |
| 2005 Q4 | 1.7 Billion USD | 5.26% |
| 2004 FY | 71 Million USD | 0.0% |
| 2004 Q2 | 71 Million USD | -21.11% |
| 2004 Q1 | 90 Million USD | -44.44% |
| 2004 Q4 | 47 Million USD | 23.68% |
| 2004 Q3 | 38 Million USD | -46.48% |
| 2003 Q4 | 162 Million USD | 26.56% |
| 2003 Q1 | 19 Million USD | 18.75% |
| 2003 Q2 | 109 Million USD | 473.68% |
| 2003 Q3 | 128 Million USD | 17.43% |
| 2002 Q3 | 33.41 Million USD | 0.0% |
| 2002 FY | 109 Million USD | 0.0% |
| 2002 Q4 | 16 Million USD | -52.11% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Bright Green Corporation | 201.78 Thousand USD | 100.0% |
| Alpha Teknova, Inc. | 13.25 Million USD | 100.0% |
| ANI Pharmaceuticals, Inc. | 309.66 Million USD | 100.0% |
| Aquestive Therapeutics, Inc. | 91.07 Million USD | 100.0% |
| Collegium Pharmaceutical, Inc. | 489.96 Million USD | 100.0% |
| Cosmos Health Inc. | 3.03 Million USD | 100.0% |
| Journey Medical Corporation | 14.62 Million USD | 100.0% |
| Embecta Corp. | 1.62 Billion USD | 100.0% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | 100.0% |
| Dynavax Technologies Corporation | 252.41 Million USD | 100.0% |
| Intra-Cellular Therapies, Inc. | 13.32 Million USD | 100.0% |
| Pacira BioSciences, Inc. | 513.79 Million USD | 100.0% |
| PainReform Ltd. | 30 Thousand USD | 100.0% |
| Sunshine Biopharma, Inc. | 539.03 Thousand USD | 100.0% |
| Sunshine Biopharma, Inc. | 539.03 Thousand USD | 100.0% |
| SCYNEXIS, Inc. | 12.15 Million USD | 100.0% |
| Safety Shot Inc | 304.9 Thousand USD | 100.0% |
| China SXT Pharmaceuticals, Inc. | 117.12 Thousand USD | 100.0% |
| Procaps Group, S.A. | 28.41 Million USD | 100.0% |
| Theratechnologies Inc. | 51.26 Million USD | 100.0% |
| Harrow Health, Inc. | 183.17 Million USD | 100.0% |
| Sonoma Pharmaceuticals, Inc. | 87 Thousand USD | 100.0% |
| Biofrontera Inc. | 804 Thousand USD | 100.0% |
| DURECT Corporation | 2.7 Million USD | 100.0% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | 100.0% |
| Cronos Group Inc. | 1.55 Million USD | 100.0% |
| OptiNose, Inc. | 611 Thousand USD | 100.0% |
| Ironwood Pharmaceuticals, Inc. | 498.3 Million USD | 100.0% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | 100.0% |
| RedHill Biopharma Ltd. | 455 Thousand USD | 100.0% |
| Organogenesis Holdings Inc. | 60.74 Million USD | 100.0% |
| Guardion Health Sciences, Inc. | - USD | NaN% |
| Cumberland Pharmaceuticals Inc. | 12.78 Million USD | 100.0% |
| Radius Health, Inc. | 339.66 Million USD | 100.0% |
| Universe Pharmaceuticals INC | - USD | NaN% |
| ProPhase Labs, Inc. | 10.25 Million USD | 100.0% |
| Phibro Animal Health Corporation | 458.28 Million USD | 100.0% |
| Procaps Group S.A. | 28.41 Million USD | 100.0% |
| Alvotech | 1.02 Billion USD | 100.0% |
| TherapeuticsMD, Inc. | 6.53 Million USD | 100.0% |
| Viatris Inc. | 16.18 Billion USD | 100.0% |
| Rockwell Medical, Inc. | 8.29 Million USD | 100.0% |
| Aytu BioPharma, Inc. | 10.87 Million USD | 100.0% |
| SIGA Technologies, Inc. | 335.99 Thousand USD | 100.0% |
| Tilray Brands, Inc. | 287.93 Million USD | 100.0% |
| Lifecore Biomedical, Inc. | 120.51 Million USD | 100.0% |
| Shineco, Inc. | 10.01 Million USD | 100.0% |
| PetIQ, Inc. | 437.82 Million USD | 100.0% |
| Incannex Healthcare Limited | 210 Thousand USD | 100.0% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | 100.0% |
| Alimera Sciences, Inc. | 64.48 Million USD | 100.0% |
| Silver Spike Investment Corp. | - USD | NaN% |
| Assertio Holdings, Inc. | 38.51 Million USD | 100.0% |
| Shuttle Pharmaceuticals Holdings, Inc. | 135.08 Thousand USD | 100.0% |
| Petros Pharmaceuticals, Inc. | 6.85 Million USD | 100.0% |
| Clever Leaves Holdings Inc. | 720 Thousand USD | 100.0% |
| Cyclo Therapeutics, Inc. | 22.48 Thousand USD | 100.0% |
| Avadel Pharmaceuticals plc | 32.75 Million USD | 100.0% |
| Hempacco Co., Inc. | 5.93 Million USD | 100.0% |
| Talphera, Inc. | - USD | NaN% |
| Alvotech | 1.02 Billion USD | 100.0% |
| Eagle Pharmaceuticals, Inc. | 56.21 Million USD | 100.0% |
| Lantheus Holdings, Inc. | 616.12 Million USD | 100.0% |
| Currenc Group, Inc. | 2.5 Million USD | 100.0% |
| Kamada Ltd. | 7.43 Million USD | 100.0% |
| Indivior PLC | 235.66 Million USD | 100.0% |
| Evoke Pharma, Inc. | 5 Million USD | 100.0% |
| Flora Growth Corp. | 942 Thousand USD | 100.0% |
| Cyclo Therapeutics, Inc. | 22.48 Thousand USD | 100.0% |
| Evolus, Inc. | 120.35 Million USD | 100.0% |
| HUTCHMED (China) Limited | 48.18 Million USD | 100.0% |
| Amphastar Pharmaceuticals, Inc. | 589.19 Million USD | 100.0% |
| Akanda Corp. | 2.49 Million USD | 100.0% |